The post-marketing surveillance of meropenem for children was conducted between May 2004 and September 2006. The safety and the efficacy were analyzed in 1210 cases and 1004 cases, respectively. The results of this surveillance were as follows: The incidence of adverse drug reactions (ADRs) associated with use of meropenem (including abnormal laboratory findings) was 14.3% (173 cases), and the main ADRs were hepatic function abnormal, alanine aminotransferase increased, and aspartate aminotransferase increased, which were similar to these observed in the clinical study. And the efficacy was 88.6% (890 cases).